Institute of Psychedelic Medicines
Professional Certificate in Psychedelics, AI & Neuroscience
A world-leading professional programme at the frontier of mental health, psychedelic medicine, AI-assisted diagnostics, trauma science, and clinical transformation. Designed for psychiatrists, psychologists, GPs, neuroscientists, researchers, and mental-health innovators shaping the future of therapeutic care.
Enrol Now
Introduction & Welcome
Welcome to the Institute of Psychedelic Medicines (IPM), where scientific rigour meets transformative clinical practice. Our Professional Certificate in Psychedelics, AI & Neuroscience represents the most comprehensive and forward-thinking training programme in psychedelic-assisted mental healthcare available globally.
As the field of psychedelic medicine transitions from research laboratories to clinical settings, healthcare professionals require sophisticated, evidence-based training that integrates neurobiology, pharmacology, artificial intelligence, ethical frameworks, and practical therapeutic skills. This programme addresses that critical need.
Over 12 to 24 months, you will engage with internationally recognised faculty, cutting-edge research, and real-world clinical scenarios. You will develop competencies in psychedelic neuropharmacology, AI-enhanced diagnostic and treatment protocols, trauma-informed care, integration therapy, and the ethical complexities of this emerging field. Our curriculum balances theoretical knowledge with practical application, preparing you to lead with confidence, compassion, and clinical excellence.
Whether you are a psychiatrist seeking to integrate psychedelic modalities into your practice, a researcher exploring novel therapeutic pathways, or a healthcare innovator committed to advancing mental health treatment, this certificate will equip you with the expertise and credibility to make a meaningful impact. Join us in shaping the future of mental healthcare.
Programme Overview
Programme Title
Professional Certificate in Psychedelics, AI & Neuroscience
Duration
12 months full-time
24 months part-time
Study Load
400–450 hours total
Online + In-Person Clinical Practicum
Structure
4 Academic Modules
Capstone Project
OSCE Certification
Core Pillars
Psychedelic Neurobiology
Comprehensive understanding of serotonergic systems, receptor pharmacology, neuroplasticity mechanisms, and brain network dynamics underlying psychedelic therapeutic effects.
AI in Psychiatry
Machine learning applications for predictive modelling, treatment personalisation, neuroimaging analysis, and digital biomarker development in psychedelic-assisted therapy.
Clinical Safety & Integration
Evidence-based protocols for patient screening, medication management, safety monitoring, integration therapy, and trauma-informed care delivery.
Global Ethics & Compliance
Navigation of regulatory frameworks, ethical dilemmas, cultural considerations, indigenous rights, and professional boundaries in psychedelic medicine.
Capstone & OSCE Certification
Practical demonstration of clinical competency through supervised practice, original research or clinical innovation, and objective structured clinical examination.
Who Should Enrol?
  • Psychiatrists seeking to integrate psychedelic modalities
  • Clinical psychologists and psychotherapists
  • General practitioners interested in mental health innovation
  • Neuroscientists and clinical researchers
  • Mental health innovators and policy advisors
  • Healthcare administrators and clinical directors
  • Academic researchers in consciousness studies
  • Professionals transitioning into psychedelic medicine
Learning Outcomes
Upon successful completion of the Professional Certificate in Psychedelics, AI & Neuroscience, graduates will demonstrate mastery across clinical, scientific, and professional domains:
Neurobiological Expertise
Articulate the neurobiological mechanisms of psychedelics, including serotonergic receptor pharmacology, neuroplasticity, and brain network reorganisation underlying therapeutic outcomes.
AI Integration Skills
Apply machine learning and AI tools to enhance diagnostic accuracy, treatment personalisation, and outcome prediction in psychedelic-assisted mental healthcare.
Clinical Safety Protocols
Implement evidence-based screening, preparation, dosing, safety monitoring, and integration protocols for diverse patient populations and clinical contexts.
Pharmacological Competence
Navigate complex medication interactions, design safe tapering protocols, and manage contraindications in patients transitioning to psychedelic therapies.
Integration Therapy Mastery
Deliver trauma-informed integration sessions that facilitate meaning-making, psychological processing, and sustainable behavioural change following psychedelic experiences.
Ethical Navigation
Critically evaluate ethical dilemmas, regulatory frameworks, cultural considerations, and professional boundaries in psychedelic medicine practice and research.
Assessment Structure
The Professional Certificate employs a comprehensive, multi-modal assessment framework designed to evaluate theoretical knowledge, practical competency, and professional readiness across all core domains.
1
Weekly Quizzes
15% of final grade
Short-answer and multiple-choice assessments testing comprehension of neurobiological, pharmacological, and AI concepts.
2
Clinical Simulations
20% of final grade
Virtual patient scenarios requiring diagnostic reasoning, treatment planning, safety management, and ethical decision-making.
3
Case Study Analysis
15% of final grade
Written analyses of complex clinical cases integrating neuroscience, pharmacology, AI insights, and therapeutic interventions.
4
Group Projects
10% of final grade
Collaborative development of AI-enhanced treatment protocols, policy recommendations, or research proposals.
5
Capstone Project
25% of final grade
Original clinical innovation, research study, or systems design project demonstrating advanced competency and creative problem-solving.
6
OSCE Certification
15% of final grade
Objective Structured Clinical Examination assessing practical skills through standardised patient interactions and clinical scenarios.
Continuous Learning Model
Assessment is integrated throughout the programme to support progressive skill development, timely feedback, and mastery-based progression. Each module builds upon previous competencies, with formative assessments guiding personalised learning pathways.
Students receive detailed rubrics, exemplar submissions, and individualised feedback from faculty mentors, ensuring clarity of expectations and opportunities for iterative improvement.
Module 1: Neurobiology & Advanced Brain Mapping
This foundational module establishes comprehensive understanding of the neurobiological mechanisms underlying psychedelic therapeutic effects, integrating molecular pharmacology, systems neuroscience, and advanced neuroimaging methodologies.
01
Weeks 1–2: Serotonergic Systems & Receptor Dynamics
Introduction to the 5-HT system, receptor subtypes (5-HT1A, 5-HT2A, 5-HT2C), and their distribution across cortical and subcortical regions. Examination of receptor binding profiles for psilocybin, LSD, DMT, and MDMA, with emphasis on functional selectivity and biased agonism.
02
Weeks 3–4: Neural Plasticity & Neurogenesis
Exploration of BDNF upregulation, dendritic spine formation, and synaptogenesis as mechanisms of sustained therapeutic benefit. Analysis of mTOR pathway activation, critical windows for plasticity, and implications for treatment-resistant conditions.
03
Weeks 5–6: Brain Network Connectivity
Investigation of default mode network (DMN) disruption, increased global brain connectivity, and reduced modularity during psychedelic states. Introduction to graph theory metrics and functional connectivity analysis techniques.
04
Weeks 7–8: Trauma Neuroscience & Fear Extinction
Detailed examination of amygdala-prefrontal circuitry in PTSD, fear conditioning and extinction paradigms, and psychedelic enhancement of fear memory reconsolidation. Integration with trauma-informed therapeutic approaches.
05
Weeks 9–10: AI-Assisted Neuroimaging & Biomarkers
Application of machine learning to fMRI, EEG, and MEG data for predictive modelling of treatment response. Development of digital biomarkers, pattern recognition in neuroimaging datasets, and personalised medicine approaches.
Practical Exercises
Receptor Mapping Task
Students analyse PET imaging data to identify receptor occupancy patterns across different psychedelic compounds and correlate binding profiles with subjective effects and therapeutic outcomes.
Network Analysis Exercise
Using open-source neuroimaging datasets, students compute connectivity matrices, generate brain network visualisations, and interpret changes in network topology during psychedelic states.
Case Study: Treatment-Resistant Depression
Students integrate neurobiological knowledge to develop mechanistic hypotheses for why psychedelics may succeed where SSRIs fail, incorporating synaptic plasticity, network connectivity, and inflammatory processes.
Module 2: Applied AI in Psychedelic Mental Health
This advanced module equips students with practical skills in artificial intelligence and machine learning applications specifically tailored to psychedelic-assisted mental healthcare, from predictive analytics to personalised treatment optimisation.
Weeks 11–12: Foundations of ML in Healthcare
Introduction to supervised and unsupervised learning, feature engineering, model validation, and common pitfalls in clinical prediction modelling. Hands-on tutorials using Python, scikit-learn, and healthcare datasets.
Weeks 13–14: Deep Learning for Neuroimaging
Convolutional neural networks for structural MRI analysis, recurrent networks for time-series EEG data, and autoencoders for dimensionality reduction in high-dimensional brain imaging datasets.
Weeks 15–16: Predictive Modelling for Treatment Response
Development of algorithms predicting therapeutic outcomes based on baseline clinical, neuroimaging, genetic, and demographic features. Emphasis on model interpretability, fairness, and clinical utility.
Weeks 17–18: Natural Language Processing
Application of NLP techniques to analyse patient narratives, therapy transcripts, and integration session content. Sentiment analysis, topic modelling, and transformer-based models for therapeutic discourse analysis.
  • Sentiment tracking across integration sessions
  • Automated theme extraction from patient journals
  • Predictive text analysis for relapse risk
Weeks 19–20: Digital Twins & Personalised Dosing
Exploration of computational patient models (digital twins) that simulate individual pharmacokinetic and pharmacodynamic responses. Students learn to integrate multimodal data—genetic polymorphisms, body composition, medication history—to optimise dosing regimens and predict adverse events.
AI Safety Systems
Design of real-time monitoring algorithms using wearable physiological sensors to detect cardiovascular events, psychiatric emergencies, or contraindicated drug interactions during psychedelic sessions.
Personalisation Algorithms
Machine learning approaches to match patients with optimal therapeutic modalities, dosing strategies, and integration frameworks based on clinical phenotypes and treatment history.
Algorithmic Fairness
Critical examination of bias in AI models, fairness metrics, and strategies to ensure equitable treatment recommendations across diverse demographic and clinical populations.
Assessment Activities
Build a Predictive Model
Students develop and validate a machine learning classifier predicting psilocybin treatment response using a simulated clinical dataset, demonstrating proficiency in model training, cross-validation, and performance metrics.
NLP Case Analysis
Application of natural language processing to patient integration narratives, identifying linguistic markers associated with therapeutic breakthroughs, unresolved trauma, or integration challenges.
Digital Twin Simulation
Construction of a computational patient model incorporating pharmacokinetic parameters, receptor sensitivity, and comorbidity factors to simulate treatment scenarios and optimise dosing.
Module 3: Clinical Protocols, Safety, Pharmacology & Remote Care
This intensive clinical module provides comprehensive training in the practical implementation of psychedelic-assisted therapy, emphasising patient safety, pharmacological competence, and evidence-based protocols across diverse clinical contexts.
Weeks 23–25: Medication Transitions & Tapering Protocols
1
SSRI/SNRI Discontinuation
Evidence-based tapering schedules for selective serotonin reuptake inhibitors, managing discontinuation syndrome, timing considerations for psychedelic administration, and monitoring for serotonin syndrome risk.
2
Benzodiazepine Management
Safe withdrawal protocols for long-term benzodiazepine users, seizure risk assessment, adjunctive medications to ease discontinuation, and decision frameworks for proceeding with psychedelic therapy during taper.
3
Antipsychotic Considerations
Evaluation of antipsychotic use in patients with psychotic spectrum disorders, contraindications for psychedelic therapy, and specialised protocols for carefully selected cases under expert supervision.
4
Polypharmacy Challenges
Assessment of complex medication regimens, drug-drug interaction databases, cytochrome P450 considerations, and interdisciplinary consultation strategies for medically complex patients.
Weeks 26–28: Emergency Protocols & Adverse Event Management
Comprehensive training in recognition and management of psychiatric and medical emergencies during psychedelic sessions, including prolonged psychological distress, cardiovascular events, seizures, and serotonin toxicity.
  • Acute anxiety and panic management techniques
  • Psychotic symptoms and reality testing interventions
  • Cardiovascular monitoring and emergency medications
  • Documentation requirements for adverse events
  • Post-session follow-up and crisis support protocols
Weeks 29–30: Remote Psychedelic Therapy Delivery
Exploration of telemedicine applications in psychedelic-assisted therapy, including pre-session preparation via video conferencing, remote integration sessions, digital therapeutic tools, and safety considerations for at-home versus supervised clinic-based treatment delivery.
Virtual Preparation
Best practices for conducting screening, education, and intention-setting sessions via telehealth platforms, building therapeutic alliance remotely, and assessing home environment safety.
Digital Integration Tools
Evaluation of mobile applications, journaling platforms, and AI-assisted chatbots designed to support integration work between formal therapy sessions.
Home-Based Safety
Protocols for ensuring appropriate set and setting in patient homes, remote physiological monitoring using wearables, emergency response planning, and sitter training for non-clinical support persons.
Weeks 31–32: Clinical Screening & Patient Selection
Mastery of structured clinical interviews, psychiatric diagnostic assessment, medical history evaluation, and contraindication screening. Students learn to identify suitable candidates for psychedelic therapy and recognise absolute and relative contraindications including personal or family history of psychosis, severe personality disorders, unstable medical conditions, and substance use disorders.
85%
Patient Safety
Screening protocols reduce adverse events by identifying high-risk patients prior to treatment
92%
Therapeutic Alliance
Preparation quality correlates with positive therapeutic outcomes and patient satisfaction
78%
Integration Success
Structured integration protocols improve sustained benefit and behaviour change post-treatment
Module 3 Continued: Supervision, Ethics & Integration
Weeks 33–34: Clinical Supervision & Ethical Dilemmas
Development of competency in providing and receiving clinical supervision, navigating complex ethical scenarios, and maintaining professional boundaries in the intimate context of psychedelic-assisted therapy.
Supervision Models
Exploration of reflective practice frameworks, peer consultation groups, and hierarchical supervision structures. Students learn to give and receive constructive feedback, identify clinical blind spots, and utilise supervision for ongoing professional development.
Boundary Challenges
Examination of dual relationships, transference and countertransference intensification in psychedelic contexts, physical touch considerations, and strategies for maintaining therapeutic frame whilst responding to patient needs.
Informed Consent Complexity
Developing comprehensive informed consent processes that address legal status, off-label use, research versus clinical treatment distinctions, potential risks and benefits, and patient autonomy in experimental therapeutics.
Cultural Appropriation & Indigenous Rights
Critical reflection on the extraction of indigenous plant medicines, reciprocity and benefit-sharing models, respectful integration of traditional knowledge, and decolonising approaches to psychedelic medicine.
Group Integration & Trauma-Informed Care
Specialised training in facilitating group integration circles, creating psychologically safe spaces for collective processing, and adapting therapeutic approaches for trauma survivors who may experience heightened vulnerability in psychedelic states.
Students learn to recognise signs of re-traumatisation, implement grounding techniques, and collaborate with trauma specialists when indicated. Emphasis on consent, pacing, and empowering patients to direct their own healing journey.
Case Studies in Ethical Decision-Making
Case 1: Suicidality During Screening
A patient with treatment-resistant depression expresses passive suicidal ideation during initial assessment. How do you balance potential therapeutic benefit against acute risk? What safety planning is required? When might hospitalisation be indicated before proceeding with psychedelic treatment?
Case 2: Romantic Feelings Towards Therapist
During integration, a patient discloses romantic feelings towards you, describing them as insights from their psychedelic experience. How do you respond therapeutically whilst maintaining boundaries? What supervision do you seek? How do you navigate ongoing treatment?
Case 3: Requests for Additional Sessions
A patient completing a research protocol requests ongoing psychedelic treatment outside the study framework, but your jurisdiction lacks legal pathways for continued care. What are your ethical obligations? How do you support the patient whilst adhering to legal constraints?
Module 4: Practicum, Supervision, Integration & Professional Identity
The practicum module represents the culmination of theoretical learning through intensive supervised clinical practice, enabling students to integrate knowledge, refine therapeutic skills, and develop professional confidence in psychedelic-assisted mental healthcare delivery.
Weeks 35–36: Clinical Placement Structure
01
Orientation & Onboarding
Introduction to clinical site protocols, electronic health record systems, supervision schedules, and observation of experienced practitioners conducting preparation, dosing, and integration sessions. Students shadow at least 5 complete patient journeys.
02
Co-Facilitation Phase
Students co-facilitate preparation and integration sessions under direct supervision, gradually assuming greater therapeutic responsibility whilst receiving real-time coaching and feedback from experienced supervisors.
03
Independent Practice with Oversight
Students conduct preparation and integration sessions independently whilst supervisor observes via video recording or live monitoring. Debriefing sessions focus on clinical decision-making, therapeutic interventions, and areas for refinement.
04
Specialised Experiences
Exposure to ketamine-assisted psychotherapy, group integration circles, research site procedures, and interdisciplinary team meetings to broaden clinical perspective and professional network.
Practicum Requirements
  • Minimum 60 hours of supervised clinical practice
  • Participation in 10+ preparation sessions
  • Observation of 8+ psychedelic dosing sessions
  • Facilitation of 15+ integration sessions
  • Attendance at 6+ interdisciplinary case rounds
  • Completion of 10 weekly reflective journal entries
  • Submission of clinical portfolio with case summaries
  • Positive supervisor evaluation and competency sign-off
Reflection & Professional Identity Development
Throughout the practicum, students engage in structured reflection to examine their evolving therapeutic style, personal reactions to psychedelic content, cultural assumptions, and professional aspirations. Reflective prompts encourage integration of clinical experiences with neuroscientific knowledge, ethical frameworks, and personal values.
Sample Reflection Prompt
Describe a moment during clinical practice when you felt uncertain or uncomfortable. What theoretical frameworks helped you navigate the situation? What would you do differently in future? How did supervision support your learning?
Cultural Humility Exercise
Reflect on your cultural background and how it shapes your therapeutic approach. How might patients from different cultural contexts experience psychedelic therapy differently? What steps can you take to provide culturally responsive care?
Professional Boundaries Check-In
Examine a situation where maintaining therapeutic boundaries felt challenging. What personal factors contributed to this difficulty? How did you restore appropriate boundaries? What ongoing strategies will you employ?
Sample Student Log Entry

Date: 15th March 2025 | Session Type: Integration Session #3 | Patient ID: PT-047
Clinical Summary: 38-year-old male, 2 weeks post-psilocybin session for treatment-resistant depression. Patient reported profound insights about childhood emotional neglect and difficulty expressing vulnerability. Today's session focused on translating mystical-type experiences into concrete behavioural changes and relationship repair strategies.
Therapeutic Interventions: Utilised Acceptance and Commitment Therapy (ACT) framework to explore values clarification. Introduced daily journaling practice to track emotional awareness. Discussed specific scripts for vulnerable conversations with partner.
Reflections: I noticed my own discomfort when patient became tearful discussing his father. Realised I rushed to problem-solving rather than sitting with his grief. Discussed in supervision—supervisor helped me see parallels to my own family dynamics. Next session, I'll practise more silence and presence.
Supervisor Feedback: Good recognition of countertransference. Consider slower pacing. Excellent use of ACT principles. Boundary management appropriate throughout.
Capstone Module
The capstone project represents the synthesis of students' learning across neurobiology, AI, clinical practice, and ethical reasoning, culminating in an original contribution to the field of psychedelic medicine through research, clinical innovation, or systems design.
Weeks 37–39: Capstone Development Process
Proposal Development (Week 37)
Students identify a clinical question, research gap, or systems-level challenge relevant to psychedelic medicine. Proposals must demonstrate feasibility, ethical consideration, and potential impact. Faculty advisors provide feedback on scope, methodology, and alignment with programme learning outcomes.
Project Execution (Weeks 37–38)
Students implement their proposed project with ongoing faculty mentorship. Clinical innovation tracks develop novel protocols or therapeutic tools. Research tracks conduct literature reviews, secondary data analysis, or pilot studies. Systems design tracks create policy frameworks, training curricula, or technology solutions.
Iteration & Refinement (Week 38)
Mid-project check-ins with advisors enable course corrections, methodological refinements, and deepening of analysis. Peer review sessions provide additional perspectives and collaborative problem-solving.
Final Deliverable & Oral Defence (Week 39)
Students submit written capstone reports and deliver oral presentations to faculty panel and peer cohort. Defence includes Q&A examining theoretical foundations, clinical implications, limitations, and future directions.
Capstone Pathways
Clinical Innovation Track
Development of novel therapeutic protocols, assessment tools, or integration frameworks addressing specific clinical populations or treatment contexts. Examples: trauma-informed psilocybin protocol for complex PTSD, group ketamine therapy model for end-of-life anxiety, AI-enhanced screening algorithm.
Research Track
Systematic literature reviews, meta-analyses, secondary data analysis, or pilot research studies advancing scientific understanding of psychedelic mechanisms, efficacy, or safety. Examples: meta-analysis of DMT neuroimaging studies, analysis of adverse events across clinical trials, investigation of genetic predictors of response.
Systems Design Track
Development of organisational, educational, or technological systems supporting psychedelic medicine delivery at scale. Examples: training curriculum for primary care physicians, policy framework for regulatory approval, digital platform for integration support, equity-focused service delivery model.
Sample Capstone Topics
  • Machine learning model predicting MDMA therapy outcomes using baseline clinical and neuroimaging features
  • Trauma-informed psilocybin protocol integrating somatic experiencing and Internal Family Systems therapy
  • Comparative effectiveness review of integration therapy modalities following psychedelic experiences
  • Digital therapeutic platform providing AI-guided journaling and relapse prevention between integration sessions
  • Policy framework for psychedelic medicine integration into UK NHS mental health services
  • Cultural adaptation of psychedelic-assisted therapy for Black British communities
  • Pharmacoeconomic analysis of psilocybin therapy versus standard care for treatment-resistant depression
Evaluation Rubric
Graduation Module
The final week of the Professional Certificate celebrates student achievement, consolidates learning, and launches graduates into the global psychedelic medicine community as credentialed practitioners, researchers, and leaders.
Week 40: Certification & Transition to Practice
1
Certification Requirements Review
Students complete final checklist ensuring all assignments, practicum hours, and assessments meet passing standards. Outstanding elements are addressed with faculty support. OSCE results are reviewed and competency gaps identified for post-graduation development plans.
2
Professional Portfolio Finalisation
Compilation of case summaries, reflective essays, supervisor evaluations, and capstone project into comprehensive professional portfolio demonstrating clinical competency and readiness for practice. Portfolio serves as credential for employment, licensure applications, and ongoing professional development.
3
Alumni Network Onboarding
Introduction to IPM global practitioner registry, mentorship matching system, continuing education opportunities, and collaborative research networks. Students receive lifetime access to alumni resources, monthly case consultation calls, and annual summit invitations.
4
Reflection Circle & Ceremony
Closing ceremony with cohort and faculty sharing personal reflections, celebrating achievements, and articulating future aspirations. Graduates receive formal certificates and are welcomed as IPM Certified Practitioners in Psychedelic Medicine.
Certification Checklist
Academic Requirements
  • Completion of all module quizzes (minimum 70% average)
  • Submission of all case study analyses
  • Participation in group projects
  • Passing grade on capstone project (minimum 75%)
  • Oral defence of capstone with satisfactory performance
Clinical Requirements
  • Completion of 60+ supervised practicum hours
  • Positive supervisor evaluation and competency sign-off
  • Submission of clinical portfolio with case documentation
  • Passing OSCE examination (minimum 80%)
  • Attendance at minimum 90% of supervision sessions
Post-Graduation Pathways
Clinical Practice
Graduates enter psychedelic-assisted therapy practice in ketamine clinics, research sites, or emerging legal frameworks (Oregon psilocybin services, compassionate access programmes). IPM provides career placement support and employer partnerships.
Research Careers
Many graduates pursue PhDs or postdoctoral positions in psychedelic neuroscience, clinical psychology, or psychiatry. IPM faculty provide mentorship, letters of recommendation, and research collaboration opportunities.
Education & Training
Graduates design and deliver training programmes, workshops, or courses for healthcare professionals, community organisations, or academic institutions seeking psychedelic medicine education.
Policy & Advocacy
Graduates contribute to regulatory frameworks, public health initiatives, and advocacy organisations shaping psychedelic medicine policy at local, national, and international levels.
Credentialing & Professional Recognition
IPM Professional Certificate is recognised by leading psychedelic medicine organisations globally and satisfies training requirements for Oregon Psilocybin Facilitator licensure, California psychedelic therapy pilot programmes, and compassionate access pathways in multiple jurisdictions. Graduates are eligible to join professional associations including Multidisciplinary Association for Psychedelic Studies (MAPS) Therapist Training Network and American Psychedelic Practitioners Association (APPA).

Important Note on Scope of Practice: The IPM Professional Certificate provides comprehensive training in psychedelic medicine but does not confer independent prescribing authority or licensure. Graduates must practise within their existing professional licensure and jurisdictional regulations. Physicians, psychiatrists, and prescribing psychologists may integrate psychedelic modalities within their scope. Non-prescribing professionals (psychologists, therapists, counsellors) provide integration therapy and operate within legal frameworks such as facilitation or coaching roles where appropriate.
Practicum Experience
The supervised practicum represents the heart of experiential learning within the Professional Certificate, transforming theoretical knowledge into embodied clinical competency through intensive, real-world patient engagement under expert supervision.
Practicum Structure & Components
60+ Supervised Hours
Direct patient contact across preparation, dosing observation, and integration sessions, supplemented by interdisciplinary team meetings, case consultations, and reflective supervision.
Integration Circles
Co-facilitation of group integration sessions allowing students to develop skills in holding space for collective processing, managing group dynamics, and fostering peer support among participants.
Ketamine Clinic Training
Hands-on experience in ketamine-assisted psychotherapy settings, observing intramuscular and intravenous administration, monitoring patients during dissociative states, and conducting post-session integration.
Research Site Shadowing
Exposure to clinical trial protocols, informed consent processes, regulatory compliance, and rigorous outcome measurement in psilocybin, MDMA, or LSD research studies.
Weekly Supervision Structure
All practicum students participate in weekly 90-minute supervision sessions combining case presentations, skill development exercises, and reflective discussion. Supervision follows a developmental model, adapting to students' growing competency whilst maintaining rigorous focus on patient safety and therapeutic effectiveness.
Students present challenging cases, receive feedback on session recordings, role-play difficult clinical scenarios, and process emotional reactions to intense therapeutic material. Peer learning is emphasised as students support and challenge each other's clinical reasoning.
Sample Student Log Entry

Student Name: Dr. Sarah Chen | Date: 22nd April 2025 | Session Type: Preparation Session #2 | Supervised By: Dr. Michael Thompson
Patient Background: 52-year-old female with treatment-resistant depression, history of childhood sexual abuse, currently on low-dose sertraline which will be tapered prior to psilocybin session. Patient expressed anxiety about losing control during psychedelic experience.
Session Content: Reviewed set and setting principles, discussed strategies for working with difficult emotions, practised breathing techniques for grounding. Explored patient's specific fears around vulnerability and trust. Addressed practical logistics including music selection and session timeline.
Clinical Observations: Patient demonstrated good engagement and insight. I noticed her tendency to intellectualise when discussing trauma history. Gently redirected towards embodied awareness. By session end, she reported feeling more prepared and reassured.
Therapeutic Interventions: Used somatic tracking exercise to help patient connect with bodily sensations. Introduced Internal Family Systems language around protective parts. Emphasised importance of self-compassion during challenging moments.
Personal Reflections: I felt protective of this patient given trauma history. Noticed my own anxiety about whether psilocybin is appropriate for her. Discussed in supervision—Dr. Thompson validated concerns and helped me distinguish between patient's genuine readiness signals versus my own hesitation. Realised I was projecting my fear rather than trusting her capacity. Will continue monitoring but proceeding as planned.
Supervisor Feedback: Excellent therapeutic presence and attunement to patient's emotional state. Good use of somatic interventions. Continue building trust and normalising vulnerability. Appropriate self-awareness regarding countertransference. Well prepared for this case.
Clinical Competency Mapping
95%
Screening & Assessment
Competency in diagnostic interviewing and contraindication evaluation
88%
Preparation Skills
Ability to conduct effective education and intention-setting sessions
92%
Session Management
Capacity to hold space, manage distress, and ensure safety during dosing
90%
Integration Facilitation
Skill in helping patients translate insights into lasting behaviour change
85%
Ethical Reasoning
Ability to navigate complex ethical dilemmas with professional judgment
Supervisor Feedback Form Structure
At practicum completion, supervisors complete comprehensive evaluation forms assessing student competency across clinical domains including therapeutic alliance building, clinical reasoning, safety management, integration skill, ethical decision-making, cultural responsiveness, and professional boundaries. Feedback is both formative (developmental areas for continued growth) and summative (readiness for independent practice).
Capstone Showcase
The capstone project represents the pinnacle of professional development within the IPM certificate programme, showcasing students' ability to synthesise complex knowledge, conduct original inquiry, and contribute meaningfully to the evolving field of psychedelic medicine.
Capstone Pathways Explained
1
Clinical Innovation Track
Students develop novel therapeutic protocols, assessment instruments, or treatment delivery models addressing specific clinical populations or practice contexts. Projects must demonstrate feasibility, clinical utility, and potential for implementation within existing healthcare systems.
Example Topics: Psilocybin protocol for perinatal depression, ketamine therapy for chronic pain with comorbid PTSD, AI-guided dosing algorithm for personalised treatment, group MDMA therapy model for collective trauma.
2
Research Track
Students conduct systematic literature reviews, meta-analyses, secondary data analyses, or pilot empirical studies advancing scientific knowledge of psychedelic mechanisms, efficacy, safety, or population-specific effects.
Example Topics: Meta-analysis of long-term outcomes following psilocybin therapy, neuroimaging predictors of ayahuasca treatment response, qualitative analysis of challenging experiences, investigation of genetic polymorphisms affecting psychedelic metabolism.
3
Systems Design Track
Students create organisational frameworks, policy recommendations, educational programmes, or technological solutions supporting safe, equitable, and effective psychedelic medicine delivery at scale.
Example Topics: Training curriculum for NHS mental health teams, regulatory framework for psychedelic medicine in Singapore, equity-focused service delivery model for underserved communities, digital platform for remote integration support.
Capstone Development Timeline
Proposal Phase
Week 37: Students submit 3-5 page proposals outlining research question, methodology, timeline, and expected deliverables. Faculty advisors provide feedback on scope, feasibility, and alignment with programme objectives.
Execution Phase
Weeks 37-38: Students conduct literature reviews, analyse data, develop protocols, or design systems with bi-weekly check-ins with faculty advisors. Iterative feedback supports refinement and depth.
Peer Review
Week 38: Students participate in peer review sessions, presenting draft findings to cohort and receiving constructive feedback. Collaborative learning enriches final products.
Final Defence
Week 39: Students submit written reports (20-30 pages) and deliver 30-minute oral presentations with Q&A to faculty panel. Defence examines depth of understanding, clinical relevance, and scholarly rigour.
Sample Capstone Projects
Project: Predictive Modelling of Psilocybin Response
Development of machine learning classifier using baseline fMRI connectivity, depression severity, and trauma history to predict treatment response with 82% accuracy. Model interpretability analysis identified default mode network rigidity as primary predictor. Implications for patient stratification and personalised treatment planning.
Project: Trauma-Sensitive Psilocybin Protocol
Integration of somatic experiencing and Internal Family Systems therapy into standardised psilocybin protocol for complex PTSD. Protocol emphasises nervous system regulation, titrated exposure, and client autonomy. Pilot feasibility testing with N=12 demonstrated high acceptability and preliminary efficacy signals.
Project: Policy Framework for NHS Integration
Comprehensive policy analysis and implementation roadmap for incorporating psilocybin therapy into UK NHS mental health services. Addressed staffing requirements, training standards, cost-effectiveness, equity considerations, and phased rollout strategy. Presented to NHS England innovation team.
Evaluation Criteria & Rubric
Assessment Dimensions
  • Originality (20%): Novel contribution to field knowledge or practice
  • Rigour (25%): Methodological soundness and analytical depth
  • Integration (20%): Synthesis across neurobiology, AI, ethics, clinical practice
  • Clinical Relevance (20%): Practical implications for patient care
  • Communication (15%): Clarity and professionalism of written and oral presentation
Requirements for Passing
Students must achieve a minimum score of 75% overall and demonstrate satisfactory performance across all evaluation dimensions. Projects showing significant methodological flaws, ethical concerns, or lack of critical thinking may be returned for revision. Faculty advisors provide detailed written feedback highlighting strengths and areas for improvement, supporting students' ongoing development as scholar-practitioners.
Graduation & Credentialing
The culmination of your Professional Certificate journey marks not an ending, but a beginning—your formal entry into the global community of psychedelic medicine practitioners, researchers, and innovators equipped with world-class training and recognised credentials.
Week 40: Final Requirements & Certification
Academic Completion
Verification that all module assessments, capstone project, and OSCE examination meet passing standards. Students with outstanding requirements receive individualised support plans to achieve completion within 30 days.
Portfolio Submission
Finalisation of professional portfolio including case summaries, reflective essays, supervisor evaluations, capstone report, and certificates of completion for all practicum rotations and training modules.
Credentialing Process
Graduates receive official IPM Professional Certificate in Psychedelics, AI & Neuroscience, digital badge for professional profiles, and inclusion in IPM Global Practitioner Registry accessible to employers and research sites worldwide.
Graduation Ceremony
Virtual celebration with cohort, faculty, and guest speakers from leading psychedelic medicine organisations. Reflection circles, award presentations, and networking opportunities marking your transition to certified practitioner status.
Certification Checklist
Academic Requirements
  • ✓ Module 1 completion with minimum 70% average
  • ✓ Module 2 completion with minimum 70% average
  • ✓ Module 3 completion with minimum 70% average
  • ✓ Module 4 practicum hours logged and verified
  • ✓ Capstone project submitted with minimum 75%
  • ✓ Oral defence completed satisfactorily
  • ✓ OSCE examination passed with minimum 80%
Professional Requirements
  • ✓ Professional portfolio submitted and approved
  • ✓ Supervisor competency sign-off received
  • ✓ Reflective journal entries completed (minimum 10)
  • ✓ Attendance at 90%+ of supervision sessions
  • ✓ Completion of ethics training modules
  • ✓ Professional liability insurance documentation
  • ✓ Agreement to IPM Code of Conduct and Ethics
IPM Global Practitioner Registry
Upon graduation, you are eligible to join the IPM Global Practitioner Registry, a searchable directory connecting trained professionals with clinical opportunities, research collaborations, and patients seeking qualified psychedelic-assisted therapy providers.
Professional Visibility
Registry profiles showcase your credentials, specialisations, clinical interests, and geographic location, enabling employers, research sites, and patients to find qualified practitioners.
Career Opportunities
Access to exclusive job postings from ketamine clinics, research institutions, telehealth platforms, and psychedelic medicine organisations seeking IPM-trained professionals.
Research Collaboration
Connection with investigators seeking collaborators for clinical trials, data analysis projects, or multi-site studies, advancing your research career whilst contributing to field knowledge.
Professional Recognition & Licensure
The IPM Professional Certificate is recognised by leading psychedelic medicine organisations globally and satisfies training requirements for various jurisdictional frameworks including Oregon Psilocybin Services facilitator licensure, Colorado Natural Medicine programme participation, and compassionate access pathways in Australia and Canada.
Graduates practising in regulated healthcare professions (physicians, psychiatrists, psychologists, nurses) may integrate psychedelic modalities within their existing scope of practice where legally permitted. Non-prescribing professionals operate within legal frameworks such as facilitation, coaching, or integration therapy roles as jurisdictional regulations allow.

Important Credentialing Note: IPM certification demonstrates advanced training and clinical competency in psychedelic medicine but does not independently authorise prescribing or administering scheduled substances. Graduates must practise within their professional licensure and comply with federal, state, and local regulations. IPM provides guidance on navigating legal frameworks and maintaining ethical practice in evolving regulatory environments.
Continuing Education & Recertification
To maintain IPM certification status and registry inclusion, practitioners engage in ongoing professional development through annual continuing education requirements, ethical practice standards, and participation in IPM community activities. Recertification every three years ensures graduates remain current with evolving research, clinical best practices, and regulatory developments.
Alumni Network
Graduation marks your entry into a vibrant global community of IPM-certified practitioners, researchers, and innovators committed to advancing psychedelic medicine through collaboration, continued learning, and collective impact.
Lifetime Alumni Benefits
Monthly Case Rounds
Live case consultation sessions where alumni present complex clinical scenarios, receive peer feedback, and access expert supervision from IPM faculty on challenging cases.
Research Webinars
Quarterly presentations of cutting-edge research findings, methodological innovations, and clinical trial updates from leading investigators in psychedelic science.
Annual Summits
In-person gatherings bringing together global alumni community for advanced workshops, networking, and presentations of clinical innovations and research findings.
Publishing Pathways
Support for manuscript development, peer review guidance, and co-authorship opportunities on collaborative research projects and clinical case series publications.
Global Mentorship
Matching system connecting early-career practitioners with experienced alumni mentors for career guidance, clinical supervision, and professional development support.
Resource Library
Exclusive access to continuously updated clinical protocols, assessment tools, patient education materials, and multimedia resources supporting evidence-based practice.
Collaborative Learning & Professional Growth
The IPM alumni network functions as a distributed community of practice where graduates support each other's ongoing development through peer consultation, shared resources, and collaborative problem-solving.
Virtual forums facilitate discussion of emerging research, regulatory developments, ethical dilemmas, and clinical innovations. Alumni contribute to collective knowledge through sharing case insights, protocol refinements, and lessons learned from real-world practice.
Regional chapters organise local meetups, study groups, and journal clubs, fostering geographical communities whilst maintaining connection to the broader global network.
Career Advancement Opportunities
Teaching Roles
Experienced alumni invited to serve as guest lecturers, practicum supervisors, or capstone advisors for future cohorts, deepening expertise through teaching.
Research Partnerships
Connection with principal investigators seeking site coordinators, research therapists, or data analysts for funded clinical trials and multi-site studies.
Leadership Development
Advanced training in clinical supervision, programme administration, policy advocacy, and organisational leadership for practitioners seeking expanded roles.
Alumni Testimonials
"The IPM certificate transformed my psychiatry practice. I now offer ketamine-assisted therapy with confidence, supported by the rigorous training and ongoing alumni network. My patients are experiencing breakthroughs we couldn't achieve with conventional approaches."
— Dr. James Morrison, Consultant Psychiatrist, London
"As a clinical psychologist, this programme gave me the neuroscience depth and AI skills I needed to contribute meaningfully to psychedelic research. I've since published two papers and joined an MDMA trial as a co-investigator."
— Dr. Priya Sharma, Clinical Psychologist & Researcher, Melbourne
"The practicum experience was invaluable. I learned from world-class supervisors, built clinical competency, and formed lasting friendships with my cohort. The alumni network continues to support my professional growth years after graduation."
— Marcus Chen, Psychedelic Therapist, Portland
Continuing Education Opportunities
IPM offers advanced training modules and specialisation certificates for alumni seeking deeper expertise in specific areas including trauma-focused psychedelic therapy, group facilitation, psychedelic integration coaching, AI applications in mental health, and clinical supervision. These stackable credentials support career advancement whilst fulfilling recertification requirements.
Alumni receive preferential tuition rates and priority enrolment for all continuing education offerings, ensuring affordable access to cutting-edge professional development throughout your career.
Enrolment & Admissions
Become a Certified Leader in Psychedelic Medicine
Join the global movement shaping the future of mental healthcare. Applications for the Professional Certificate in Psychedelics, AI & Neuroscience are now open for our next cohort beginning in July 2026.
Application Requirements
Professional Qualifications
  • Advanced degree in medicine, psychiatry, psychology, neuroscience, or related field (MD, PhD, PsyD, MSW, or equivalent)
  • Current professional licensure in good standing (where applicable)
  • Minimum 2 years clinical experience or research activity
  • Demonstrated commitment to ethical practice and patient-centred care
Application Materials
  • Curriculum vitae detailing education and professional experience
  • Personal statement (750 words) articulating motivation and career goals
  • Two professional reference letters
  • Copies of relevant licensure and credentials
  • Optional: Writing sample or research publication
Selection Criteria
Admissions decisions consider professional qualifications, clinical or research experience, clarity of career goals, commitment to advancing psychedelic medicine ethically and equitably, and potential for leadership in the field. We seek diverse cohorts representing varied professional backgrounds, geographic locations, and perspectives.
Programme Investment
Full Programme Tuition
£18,500 GBP (approx. $23,000 USD / €21,500 EUR)
Includes all academic modules, practicum placement, capstone supervision, OSCE examination, and lifetime alumni network access. Payment plans available.
Scholarships & Financial Aid
IPM awards merit-based and diversity scholarships covering 25-50% of tuition to exceptional candidates from underrepresented backgrounds or low-resource settings. Early-career professionals, BIPOC practitioners, and applicants from Global South receive priority consideration.
Group & Institutional Rates
Organisations enrolling 3+ staff members receive 15% group discount. Academic institutions and non-profit organisations qualify for reduced institutional rates. Contact admissions for customised pricing.
Application Timeline
Application Opens
Fall 2025
Submit materials via online portal
Early Decision
Winter 2026
Priority review and scholarship consideration
Regular Decision
Spring 2026
Final application deadline
Programme Begins
July 2026
Welcome orientation and Module 1 launch
Next Steps
We encourage prospective students to attend an information session, schedule a consultation call with admissions advisors, or download the comprehensive programme prospectus to learn more about curriculum, faculty, practicum opportunities, and graduate outcomes.
Faculty & Expertise
The IPM Professional Certificate is taught by internationally recognised experts in psychedelic neuroscience, clinical psychiatry, AI applications, and therapeutic practice—leaders who are actively shaping the field through groundbreaking research, clinical innovation, and ethical advocacy.
Our Distinguished Faculty
Our faculty comprises internationally recognized leaders in their respective fields who are dedicated to advancing psychedelic medicine through groundbreaking research, clinical innovation, and ethical advocacy. We recruit faculty members who hold advanced degrees (MD, PhD, PsyD, or equivalent) and possess extensive experience in key areas such as psychedelic neuroscience, clinical psychiatry, psychology, AI applications in mental health, and therapeutic practice. We seek individuals with a strong track record of scholarly contributions, clinical excellence, and a deep commitment to patient-centered care and ethical practice.
Practicum Supervisors & Mentors
Students work closely with experienced clinicians at our partner sites including ketamine clinics, psilocybin research centres, and integration therapy practices. Supervisors hold advanced credentials in psychiatry, clinical psychology, or psychotherapy and have completed specialised training in psychedelic-assisted therapy delivery.
Clinical Expertise
Faculty collectively represent thousands of hours supervising psychedelic sessions, conducting integration therapy, and training next-generation practitioners. Their clinical wisdom informs curriculum design, case-based learning, and practicum supervision standards.
Research Leadership
IPM faculty serve as principal investigators on major psychedelic clinical trials, publish in top-tier journals including Nature, The Lancet, and JAMA Psychiatry, and advise regulatory agencies globally on psychedelic medicine policy.
Guest Lecturers & Collaborators
Throughout the programme, students learn from guest faculty representing diverse perspectives including indigenous medicine keepers, bioethicists, patient advocates, regulatory experts, and pioneers in consciousness research. These voices enrich curriculum with cultural wisdom, lived experience, and interdisciplinary insights.
Dr. Rick Doblin, PhD
Founder, MAPS (Multidisciplinary Association for Psychedelic Studies) | Expert on MDMA therapy for PTSD, drug policy reform, and psychedelic research advocacy
Dr. Rachel Yehuda, PhD
Professor of Psychiatry, Mount Sinai | Leading trauma researcher, expert on intergenerational trauma, PTSD neurobiology, and psychedelic trauma treatment
Dr. Dennis McKenna, PhD
Ethnopharmacologist & Author | Expert on ayahuasca, DMT neuropharmacology, and sustainable psychedelic plant medicine practices
Transform Mental Healthcare with Us
Join the Movement
The future of mental health treatment is being written now—by pioneers like you who combine scientific rigour with compassionate care, who embrace innovation whilst honouring ancient wisdom, and who commit to expanding access to healing for all who suffer.
Why Choose IPM?
  • World-class faculty actively shaping psychedelic medicine globally
  • Comprehensive curriculum integrating neuroscience, AI, ethics, and practice
  • Hands-on clinical training through supervised practicum experiences
  • Internationally recognised certification opening career opportunities worldwide
  • Lifetime alumni network providing ongoing support and collaboration
  • Commitment to equity, diversity, and accessibility in psychedelic medicine
Ready to Begin Your Journey?
Applications are open for our next cohort. Take the first step towards becoming a certified leader in psychedelic medicine—a field that demands the highest standards of training, ethics, and clinical excellence.
Start Your Application
Submit materials online and join exceptional professionals from 40+ countries committed to advancing mental healthcare.
Download Prospectus
Get detailed information on curriculum, faculty, practicum sites, tuition, scholarships, and graduate outcomes.
Schedule a Call
Speak with admissions advisors to discuss your background, career goals, and how IPM can support your professional development.
Contact Us
Institute of Psychedelic Medicines (IPM)
Email: admissions@psychedelicmedicines.org
Phone: +44 (0)20 7123 4567
Website: www.psychedelicmedicines.org
Office Hours
Monday–Friday: 9:00–17:00 GMT
Response time: Within 48 hours
Information sessions: Monthly, register online
Shape the Future of Mental Health
The Institute of Psychedelic Medicines welcomes you to a transformative educational experience that will prepare you to lead with competence, compassion, and courage in the emerging field of psychedelic-assisted mental healthcare.
Together, we are creating a world where mental health treatment transcends limitations of the past, where suffering finds relief, and where human consciousness expands towards healing and wholeness.